Rationale: Given that tetrahydrocannabinol (THC) and nicotine have similar effects on negative affect (NA), we hypothesized that a 7-mg nicotine patch (NP) would reduce NA-related cannabis (CAN) withdrawal symptoms in cannabis-dependent (CD) individuals who were not nicotine dependent.
Objective: We sought to determine whether NP reduces NA across 15 days of CAN abstinence in two groups: non-tobacco smokers (NTS) and light tobacco smokers (LTS).
Methods: CD participants (N = 127; aged 18-35) who used CAN at least 5 times/week for the past 12 + months were randomized to (1) NP or (2) a placebo patch (PP) and received $300 for sustained biochemically verified CAN abstinence. Of those randomly assigned, 52 of 63 NP, and 56 of 64 PP maintained biochemically verified CAN abstinence and 51 NP and 50 PP participants complied with all aspects of the study. Affect and other withdrawal symptoms were measured every 48 h across 15 days of CAN abstinence.
Results: After controlling for age, tobacco use, baseline THC concentration, and baseline measurements of the dependent variable, NP reduced NA symptoms across the 15-day treatment relative to PP. Differences in NA and CAN withdrawal symptoms were not moderated by tobacco user status.
Conclusions: The findings provide the first evidence that NP may be able to attenuate NA-related withdrawal symptoms in individuals with cannabis use disorder who are not heavy users of tobacco or nicotine.
Clinical Trials Registry: NCT01400243 http://www.clinicaltrials.gov.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00213-020-05476-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Large library docking of tangible molecules has revealed potent ligands across many targets. While make-on-demand libraries now exceed 75 billion enumerated molecules, their synthetic routes are dominated by a few reaction types, reducing diversity and inevitably leaving many interesting bioactive-like chemotypes unexplored. Here, we investigate the large-scale enumeration and targeted docking of isoquinuclidines.
View Article and Find Full Text PDFLongitudinal Cross-Lagged Analysis Between Depressive Symptoms, Social Withdrawal, Self-Esteem, and School Adaptation in Multicultural Adolescents.
Psychol Belg
January 2025
College of General Education, Kookmin University, Seoul, South Korea.
In Korea, as the number of multicultural families formed through the marriage of Korean men and foreign women from lower-income countries such as China, Southeast Asia, and Central Asia increases, the psychosocial adaptation of adolescents from these families is becoming increasingly important. This study examines the longitudinal and reciprocal relationships among depressive symptoms, social withdrawal, self-esteem, and school adaptation in multicultural adolescents in high schools. We applied an autoregressive cross-lagged model to a sample of 594 multicultural adolescents extracted from three consecutive years of data from the Multicultural Adolescents Panel Survey and found that depressive symptoms and school adaptation had reciprocal negative relationships in multicultural adolescents' first and second years of high school.
View Article and Find Full Text PDFA case of relapsed gAChR-positive autoimmune autonomic ganglionopathy treated by plasma exchange and mycophenolate mofetil.
Front Neurol
January 2025
Department of Neurology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China.
Autoimmune autonomic ganglionopathy (AAG) is a rare and acquired immune-mediated disease that leads to wide autonomic failure, mainly characterized by orthostatic hypotension, gastrointestinal dysfunction, anhidrosis and poorly reactive pupils. This disorder is usually associated with autoantibodies to the ganglionic nicotinic acetylcholine receptor (gAChR-Ab). In this study, we describe a case of a gAChR-Ab-positive AAG patient with two therapeutic stages.
View Article and Find Full Text PDFEfficacy and Safety of Altibrain® as an Adjunctive Therapy for Autism Spectrum Disorder: An Open Label Trial Targeting Core Symptoms.
Curr Pharm Des
January 2025
Director Operations and Medical Writing, RYT Lifesciences Pvt Ltd, Ahmedabad, Gujrat, India.
Objective: This study aimed to evaluate the effectiveness and safety of Altibrain® in combination with standard Autism Spectrum Disorder (ASD) treatment compared to standard ASD treatment alone in individuals diagnosed with ASD.
Method: A randomized, open-label trial was conducted involving 120 participants aged 3 to 17 years, randomly assigned to either the Standard ASD Treatment group or the Altibrain® + Standard ASD Treatment group. Sixty patients were randomly allocated to each Standard ASD Treatment group or the Altibrain® + Standard ASD Treatment group.
Ethnicity predicts long-term depressive symptom patterns in older adults with type 2 diabetes.
Int Psychogeriatr
January 2025
Department of Psychology, Lehman College/City University of New York, Bronx, NY 10468, USA; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address:
Objectives: Depression is a chronic disorder that significantly affects functional decline in older adults, especially those with type 2 diabetes (T2D). Ethnic groups may experience different depression risks and severities, yet the effect of ethnicity on depression trajectories and specific dimensions in older adults with T2D remains largely unexamined. We examined the longitudinal associations of ethnicity with depression and its specific dimensions over time in older Ashkenazi and non-Ashkenazi Jews with T2D.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!